Silica Nanoparticles Drive 5-of-10 Prostate Cancer Remissions in Mice With Immunotherapy
Updated
Updated · ScienceDaily · Jul 9
Silica Nanoparticles Drive 5-of-10 Prostate Cancer Remissions in Mice With Immunotherapy
3 articles · Updated · ScienceDaily · Jul 9
Summary
Five of 10 mice with aggressive prostate cancer achieved complete remission when Weill Cornell’s targeted silica nanoparticles were paired with checkpoint immunotherapy and a CSF-1R blocker; nanoparticles plus immunotherapy alone produced four of 10 remissions.
The PSMA-targeted particles appeared to kill tumor cells by triggering ferroptosis—an iron-linked form of oxidative cell death—while turning immune-resistant “cold” tumors into immune-active “hot” ones.
Researchers said the treatment also reprogrammed T cells, macrophages and tumor metabolism, helping approved immunotherapy work better in a cancer where durable responses have been hard to achieve.
The amorphous silica C' dots, already in late-stage trials for imaging-related uses, showed no signs of toxicity outside tumors in the mouse studies despite brief buildup in organs such as the spleen.
The findings are preclinical, and the team’s next goal is to test safety and effectiveness in human clinical trials.
This new therapy cured half the mice; what's the next step to bring this potential breakthrough to humans?
How do these tiny particles teach the immune system to attack previously resistant 'cold' tumors?
C' Dots Achieve 50% Complete Remission in Preclinical Prostate Cancer Models: Dual-Action Nanotherapy Poised for Clinical Trials
Overview
A major breakthrough in prostate cancer treatment has emerged from preclinical research by Weill Cornell Medicine and Cornell Engineering. The study shows that engineered silica nanoparticles, called C' dots, can induce significant remissions in aggressive prostate cancer mouse models, especially when combined with immunotherapy. C' dots work through a dual mechanism: they directly kill tumor cells via ferroptosis and also help remodel the tumor’s immune environment, making it more responsive to treatment. These promising results highlight the potential of C' dots as a new, effective approach for treating aggressive prostate cancer.